DNA repair/replication transcripts are down regulated in patients with Fragile X Syndrome
© Xu et al.; licensee BioMed Central Ltd. 2013
Received: 30 July 2012
Accepted: 22 February 2013
Published: 11 March 2013
Fragile X Syndrome (FXS) and its associated disorders are caused by the expansion of the CGG repeat in the 5’ untranslated region of the fragile X mental retardation 1 (FMR1) gene, with disease classification based on the number of CGG repeats. The mechanisms of repeat expansion are dependent on the presence of cis elements and the absence of trans factors both of which are not mutually exclusive and contribute to repeat instability. Expansions associated with trans factors are due to the haploinsuffient or reduced expression of several DNA repair/metabolizing proteins. The reduction of expression in trans factors has been primarily conducted in animal models without substantial examination of many of these expansion mechanisms and trans factors in humans.
To understand the trans factors and pathways associated with trinucleotide repeat expansion we have analyzed two microarray datasets which characterized the transcript expression in patients with FXS and in controls.
We observed significant down regulation of DNA damage/repair pathway transcripts. This observation was consistent in both datasets, which used different populations. Within these datasets, several transcripts overlapped in the direction of association and fold change. Further characterization of these genes will be critical to understand their role in trinucleotide repeat instability in FXS.
KeywordsHaploinsufficiency FMR1 DNA repair/replication proteins
Fragile X Syndrome (FXS, OMIM 300624) is caused by a mutation in fragile X mental retardation 1 (FMR1). Prevalence estimates for FXS in the general Caucasian population is ~1 out of 4000 males and ~1 out of 8000 females [1, 2]. This prevalence rate has been subsequently substantiated by other reports, thus the rate is generally regarded as the prevalence rate in a randomly mating population . FXS is a spectrum disorder in which affected individuals have IQs ranging from low or moderate to high functioning [4, 5]. In over 98% of patients, FXS is caused by expansion of the CGG repeats in the 5’ untranslated region of FMR1 located adjacent to exon1 on the X chromosome [6, 7]. The CGG repeat region can be grouped into four general allelic forms, based on the CGG repeat length and stability, during transmission from parent to child. The allelic forms include common variants containing 6–40 repeats; intermediate variants, sometimes termed gray zone alleles, containing 41–54 repeats; premutation variants containing 55–199 repeats; and the full mutation variants, containing >200 repeats . When the expansion exceeds 200 CGG repeats (i.e. full mutation), it causes methylation of the FMR1 regulatory region, which induces transcriptional silencing . This CGG repeats are periodically interspersed with AGG interruptions; interestingly the presence of these AGG interruptions in the CGG repeat have been shown to reduced the risk of transmission of a full mutation to offspring . The transmission of the FXS full mutation is usually maternally derived because sperm from males with a premutation or a full mutation only carry premutation alleles; however one case of a premutation male who transmitted a full mutation to his daughter is reported in the literature .
Similar to other trinucleotide expansion disorders (e.g., myotonic dystrophy, Huntington disease, and some spinocerebellar ataxias) FXS CGG repeat expansions are locus specific; that is, genome-wide instability is not observed. This suggests that the mechanism of repeat expansions might not be caused by mutations in the DNA repair proteins or other trans acting factors, as such factors typically lead to genome-wide instability (e.g., several colorectal cancers and diseases ).
Other mechanisms have been proposed to produce trinucleotide repeat expansions that do not require a mutation phenotype . One mechanism suggests the alternation of the stoichiometric amount of protein product needed to maintain genomic integrity could underlie trinucleotide repeat expansions without the mutation phenotype. For example, a reduction in the stoichiometric ratio of enzymes critical for DNA repair/replication leading to locus-specific expansions has been investigated in animal models [13, 14]. Haploinsufficiency has mainly focused on the proteins in the ATM/ATR pathway to understand the intergenerational expansions of CGG repeats [13, 14]. Reports have clearly demonstrated that haploinsufficiency of ATR and ATM (kinases that function in resolution of stalled replication forks and in double strand breaks, respectively) leads to increased intergenerational expansion of CGG repeats with a maternal and paternal bias, respectively [13, 14]. Corroborating evidence of haploinsufficient expression of DNA repair/replication protein transcripts has not been reported in humans. Recently, expression analysis of transcripts has occurred in patients with FXS [15–18]. We used two datasets to determine if expression transcripts of DNA repair/replication enzymes were significantly altered in patients with FXS compared to controls. We observed that within both datasets there was significant down regulation of several enzymes with characterized functions in DNA repair and replication. In addition, both datasets also showed an overlap of several proteins important in maintaining genomic integrity.
Genes in DNA repair/replication pathways were compiled from the REACTOME pathway database (http://www.reactome.org). FXS expression array data were obtained from two sources. First, microarray expression dataset GSE7329 was downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) database . In this dataset, expression profiles of blood-derived lymphoblastoid cells from males with autism due to a fragile X mutation (FMR1-FM), or autism due to a 15q11-q13 duplication (dup(15q)), or individuals without autism spectrum disorders (i.e. controls), were studied using Agilent Whole Human Genome Oligo Microarray G4112A. Probes corresponding to the compiled list of genes in DNA repair/replication pathways were identified on the Agilent Whole Human Genome Array. Log (base 10) transformed expression values were extracted from the downloaded GSE7329 dataset directly. Analysis of Variance (ANOVA), followed with specific contrast between FXS and control groups, was conducted in Partek Genomics Suite 6.5 (Partek, Inc., St. Louis, Missouri, USA). Second, gene expression related to DNA repair/replication pathways were also assessed using data from our collaborators. Recently, Rosales-Reynoso and colleagues published a gene expression profiling study of the total peripheral blood from 10 male patients with FXS and 10 controls . Two-color Human Genome Microarray (MWG Biotech H10K_DB) from the Physiology Laboratory of the Universidad Nacional Autónoma de México (http://microarrays.ifc.unam.mx) was used for this study. Target preparation, hybridization, and initial data collection were performed according to the Physiology Laboratory’s in-house protocol. Signal quantification and normalization were determined using the Array-Pro Analyzer 4.0 software for microarray images (Media Cybernetics, L.P., Silver Spring, MD). Details about the experiment protocol have been described previously . Probes corresponding to the compiled list of genes in DNA repair/replication pathways were extracted from the dataset. One sample t-test was conducted for the Log transformed expression intensity ratios between pairs of patients with FXS and controls in Partek Genomics Suite 6.5. False discovery rate control (FDR < 0.05) was applied to indentify the differentially regulated genes.
DNA damage/repair genes which overlap in both datasets with similar fold-change and direction of association
FDR corrected p-value
Fold change(FX vs. con)
Fold-change direction(FX vs. con)
Transcript expression data may not have a linear association with translation; subsequent in vitro follow-up is needed to determine whether differential expression of transcripts in the DNA repair/replication pathway corresponds to alteration of protein levels in these enzymes. Further investigations are needed to provide models which couple decreased expression of DNA repair/replication enzymes with the mechanism of trinucleotide repeat expansion in patients with FXS. Other evidence from mouse models also shows a maternal and paternal bias in the inheritance of expanded repeats based on specific DNA replication/repair enzyme [12, 13]. In addition, familial studies of intergeneration expansion have indicated evidence of different expansion rates . This suggests that characterizing the mode of inheritance of the CGG expansion (i.e., whether primarily maternal or paternal) would be significant in understanding the inheritance. In effect, the mode of inheritance would provide significant data leading to an understanding of the enzymes which are significantly associated with expansion pathways.
Currently, only around 16 genes were found to be differentially regulated with the direction of association similar in both datasets. The limited number of genes found through this analysis is due to the fact that two different microarray experiments did not have a large number of overlapping genes for the DNA damage/repair pathway from REACTOME. We found that the degree of overlap between both datasets was around 50%. However, within this limited amount of data we found significant associations which we hope can be replicated by others. Overall, these findings indicate that the DNA damage/repair pathways could significantly contribute to repeat instability.
The current understanding of trinucleotide expansion disorders suggests that many of these expansions arise from several different mechanisms . A second level of complexity would also suggest that the DNA repair/replication mechanisms could have considerable cross talk . Understanding the mechanism of trinucleotide repeat expansion in FXS would be beneficial to understanding other trinucleotide repeat expansion disorders. Finally, the evolutionary significance of loci-specific repeat expansion disorders should not be understated. Evidence from this field could engender greater understanding of the evolution of the human genome and a greater understanding of how genome fidelity is maintained.
Ataxia telangiectasia and Rad3 related
Ataxia telangiectasia mutated
Analysis of Variance
False discovery rate
Fragile X mental retardation 1 gene
Fragile X Syndrome
Gene Expression Omnibus
National Center for Biotechnology Information
8-oxoguanine DNA glycosylase
Online Mendelian Inheritance in Man
DNA repair exonuclease rad9 homolog A
HX and EP are supported by the National Institutes of Health (US), MRR and PBN are supported by the Health Research Coordination of the Mexican Institute of Social Security.
- Crawford D, Acuna J, Sherman S: FMR1 and the Fragile X syndrome: human genome epidemiology review. Genet Med. 2001, 3 (5): 359-371. 10.1097/00125817-200109000-00006.PubMedPubMed CentralView ArticleGoogle Scholar
- Garber K, Smith K, Reines D, Warren S: Transcription, translation and Fragile X Syndrome. Curr Opin Genet Dev. 2006, 16: 270-275. 10.1016/j.gde.2006.04.010.PubMedView ArticleGoogle Scholar
- Coffee B, Keith K, Albizua I, Malone T, Mowery J, Sherman S, Warren S: Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009, 85: 503-514. 10.1016/j.ajhg.2009.09.007.PubMedPubMed CentralView ArticleGoogle Scholar
- Fengler S, Fuchs S, Konig R, Arnemann J: Mosaicism for FMR1 and FMR2 deletion: a new case. J Med Genet. 2002, 39: 200-201. 10.1136/jmg.39.3.200.PubMedPubMed CentralView ArticleGoogle Scholar
- Han X-D, Powell B, Phalin J, Chehab F: Mosaicism for a Full mutation, Premutation and Deletion of the CGG Repeats results in 22% FMRP and elevated FMR1 mRNA levels in a high functioning Fragile X male. Am J Med Genet A. 2006, 140A: 1463-1471. 10.1002/ajmg.a.31291.View ArticleGoogle Scholar
- Fu Y, Kuhl D, Pizzuti A, Pieretti M, Sutcliffe J, Richards S, Verkerk A, Holden J, Fenwick R, Warren S: Variation of the CGG repeat at the Fragile X site results in gene instability: resolution of the Sherman paradox. Cell. 1991, 67: 1047-1058. 10.1016/0092-8674(91)90283-5.PubMedView ArticleGoogle Scholar
- Verkerk A, Pieretti M, Sutcliffe J, Fu Y, Pizzuti A, Reiner O, Richards S, Victoria M, Zhang F: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in Fragile X syndrome. Cell. 1991, 65: 905-914. 10.1016/0092-8674(91)90397-H.PubMedView ArticleGoogle Scholar
- Sutcliffe J, Nelson D, Zhang F, Pieretti M, Caskey T, Saxe D, Warren S: DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992, 1: 397-400. 10.1093/hmg/1.6.397.PubMedView ArticleGoogle Scholar
- Yrigollen CM, Durbin-Johnson B, Gane L, Nelson DL, Hagerman R, Hagerman PJ, Tassone F: AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genet Med. 2012, 14 (8): 729-736. 10.1038/gim.2012.34.PubMedPubMed CentralView ArticleGoogle Scholar
- Zeesman S, Zwaigenbaum L, Whelan D, Hagerman R, Tassone F, Taylor S: Parental Transmission of Fragile X Syndrome. Am J Med Genet A. 2004, 129A: 184-189. 10.1002/ajmg.a.30191.PubMedView ArticleGoogle Scholar
- Foulkes W: Inherited susceptibility to common cancers. N Engl J Med. 2008, 359: 2143-2153. 10.1056/NEJMra0802968.PubMedView ArticleGoogle Scholar
- McMurray CT: Mechanisms of trinucleotide repeat instability during human development. Nat Rev Genet. 2010, 11 (11): 786-799. 10.1038/nrg2828.PubMedPubMed CentralView ArticleGoogle Scholar
- Entezam A, Usdin K: ATM and ATR protect the genome against two different types of tandem repeat instability in Fragile X premutation mice. Nucleic Acids Res. 2009, 37 (19): 6371-6377. 10.1093/nar/gkp666.PubMedPubMed CentralView ArticleGoogle Scholar
- Entezam A, Usdin K: ATR protects the genome against CGG. CCG-repeat expansion in Fragile X premutation mice. Nucleic Acids Res. 2008, 36 (3): 1050-1056.PubMedPubMed CentralView ArticleGoogle Scholar
- Rosales-Reynoso MA, Ochoa-Hernandez AB, Aguilar-Lemarroy A, Jave-Suarez LF, Troyo-Sanroman R, Barros-Nunez P: Gene expression profiling identifies WNT7A as a possible candidate gene for decreased cancer risk in fragile X syndrome patients. Arch Med Res. 2010, 41 (2): 110-118. 10.1016/j.arcmed.2010.03.001.PubMedView ArticleGoogle Scholar
- Nishimura Y, Martin CL, Lopez AV, Spence SJ, Alvarez-Retuerto AI, Sigman M, Steindler C, Pellegrini S, Schanen NC, Warren ST: Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Hum Mol Genet. 2007, 16 (14): 1682-1698. 10.1093/hmg/ddm116.PubMedView ArticleGoogle Scholar
- Urbach A, Bar-Nur O, Daley GQ, Benvenisty N: Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell. 2010, 6 (5): 407-411. 10.1016/j.stem.2010.04.005.PubMedPubMed CentralView ArticleGoogle Scholar
- Bittel DC, Kibiryeva N, Butler MG: Whole genome microarray analysis of gene expression in subjects with fragile X syndrome. Genet Med. 2007, 9 (7): 464-472. 10.1097/GIM.0b013e3180ca9a9a.PubMedView ArticleGoogle Scholar
- Nolin SL, Lewis FA, Ye LL, Houck GE, Glicksman AE, Limprasert P, Li SY, Zhong N, Ashley AE, Feingold E: Familial transmission of the FMR1 CGG repeat. Am J Hum Genet. 1996, 59 (6): 1252-1261.PubMedPubMed CentralGoogle Scholar